CytRx is a biopharmaceutical company focused on discovering and developing new therapeutics to treat patients with high unmet needs.
CytRx has a milestone and royalty agreement with Orphazyme A/S (“ORPHA.CO”) for arimoclomol. The agreement can provide CytRx with up to $120M in potential milestones + royalties paid on arimoclomol. Orphazyme is currently studying arimoclomol in clinical trials for 4 indications including ...
CytRx is a biopharmaceutical company focused on discovering and developing new therapeutics to treat patients with high unmet needs.
CytRx has a milestone and royalty agreement with Orphazyme A/S (“ORPHA.CO”) for arimoclomol. The agreement can provide CytRx with up to $120M in potential milestones + royalties paid on arimoclomol. Orphazyme is currently studying arimoclomol in clinical trials for 4 indications including Nieman-Pick disease Type C (NPC), amyotrophic lateral sclerosis (ALS), Gaucher disease and sporadic Inclusion Body Myositis (sIBM). Recently, Orpahzyme announced encouraging clinical trial data with arimoclomol in NPC.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.